EGFR and non-small cell lung carcinoma: Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been developed and approved by the FDA for the treatment of non-small-cell lung cancer, but their efficacy may be compromised by drug resistance in EGFR-mutant variants (Sharma et al., 2007; Hirsch et al., 2017).